SAN ANTONIO--(BUSINESS WIRE)--
- 170 million people in North and South America have sleep apnea, ResMed study finds
- Researchers urge more screenings and cloud-connected treatment devices to curb growing health crisis
ResMed (RMD) (RMD.AX) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society.
The study, a deeper analysis of ResMed’s 2018 finding that 936 million people worldwide have sleep apnea, concludes that:
- 170 million people in North and South America (37 percent of adults) have sleep apnea, based on the AASM 2012 criteria – a “conservative” estimate.
- 3 countries with the highest number of cases are the United States (54 million), Brazil (49 million), and Colombia (11 million).
Sleep apnea is a chronic disease in which people stop breathing for 10 seconds or more throughout the night, repeatedly waking to breathe and prevent suffocation. While sufferers rarely remember waking up, the disruptive cycle causes chronic sleep deprivation, which is linked to daytime fatigue, increases the risk in road and workplace accidents, and is common among people with other diseases like heart failure, high blood pressure, obesity, and type 2 diabetes.
“Previous estimates stated 100 million worldwide have sleep apnea. Now we know it’s nearly double that in just the Americas alone,” said study coauthor and ResMed Chief Medical Officer Carlos M. Nunez, M.D. “Given how common sleep apnea is, especially among people with other common diseases, doctors should screen their high-risk patients and help those who are diagnosed get onto life-changing treatment as soon as possible.”
The gold standard treatment for sleep apnea is a positive airway pressure (PAP) device that prevents the intermittent suffocation associated with sleep apnea by blowing a mild stream of air into the upper airway to keep it open and maintain breathing during sleep.
PAP devices that are cloud-connectable, enabling remote and self-monitoring, have shown to raise adherence rates above 80 percent, compared to roughly 50 percent on non-cloud connected devices.
“Digital health can show patients how well they’re doing on treatment, coach them on how to improve, and motivate them by celebrating milestones they’ve reached,” Nunez said. “These features all help drive patient adherence, which is critical if we’re going to help millions reduce the short- and long-term risks associated with sleep apnea.”
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.